Neovacs S.A.
NEOVACS TO PRESENT AT 2015 BIO INTERNATIONAL CONVENTION
Neovacs S.A. / Key word(s): Conference
NEOVACS TO PRESENT AT 2015 BIO INTERNATIONAL CONVENTION
Company to Highlight Active Immunotherapy Platform Focused on Autoimmune Diseases and Cancer Paris and Boston, June 3, 2015 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases and solid tumors, announced today that it has been selected to present at the 2015 BIO International Convention to be held in Philadelphia, June 15-18, 2015. Neovacs has strengthened its position in the U.S. since 2014, notably with : – The installation of its Scientific Advisory Board in New York City; – The creation of a U.S. subsidiary, Neovacs, Inc, in Boston; – The preparation of U.S.-based clinical trials with IFNα-Kinoid; – Participation in key U.S. investor conferences Neovacs’ participation at BIO 2015 corresponds with these U.S. expansion efforts. Neovacs will have its own booth within the French Pavillion1 where CEO Miguel Sieler will present recent information on the Company’s proprietary active immunotherapy platform for the treatment of auto-immune diseases and solid tumors on Tues., June 16 at 4:15 p.m. EDT. BIO International Convention is the world’s largest biotechnology convention, gathering several thousand companies from the global biotechnology and pharmaceutical industry. More information on BIO 2015 is available at http://convention.bio.org/2015/. For more information on Neovacs, please visit www.neovacs.fr
Investor Relations / Financial Communications – NewCap Investor Relations / Financial Communications Germany – MC Services Press / U.S. Inquiries – The Ruth Group 2015-06-03 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | Neovacs S.A. | |
3-5, Impasse Reille | ||
75014 Paris | ||
France | ||
Phone: | +33 (0)1 53 10 93 00 | |
Fax: | +33 (0)1 53 10 93 03 | |
E-mail: | www.neovacs.fr | |
Internet: | info@neovacs.fr | |
ISIN: | FR0004032746 | |
WKN: | A1CVKR | |
Listed: | Regulated Unofficial Market in Stuttgart; Open Market in Frankfurt | |
End of News | DGAP News-Service |
364743 2015-06-03 |